Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer

Yoshii,Hidehiko; Ito,Keiichi; Asano,Takako; Horiguchi,Akio; Hayakawa,Masamichi; Asano,Tomohiko

doi:10.3892/or.2013.2577

Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer

Authors:
- Hidehiko Yoshii
- Keiichi Ito
- Takako Asano
- Akio Horiguchi
- Masamichi Hayakawa
- Tomohiko Asano
View Affiliations

Affiliations: Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
Published online on: July 1, 2013 https://doi.org/10.3892/or.2013.2577
Pages: 1073-1080

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the association between clinicopathological parameters and α-actinin-4 (ACTN4) expression in bladder cancer specimens was evaluated, and the functional role of ACTN4 in bladder cancer cells was investigated. Immunohistochemistry using anti-ACTN4 antibody was performed in bladder cancer specimens (53 superficial and 42 muscle-invasive cases) from 95 patients who underwent radical cystectomy (n=46) or transurethral resection (TUR) only (n=49). We divided the levels of ACTN4 expression into 2 groups (low or high) by comparing the staining intensity in each specimen with that of the vascular endothelial cells in the same specimen, and we evaluated the correlations between these levels and pathological parameters, recurrence and prognosis. We also investigated the effects of ACTN4 suppression by siRNA on the invasive ability and proliferation of T24 and KU19-19 cells. High ACTN4 expression was significantly associated with higher tumor grade and higher pT stage. In patients with superficial bladder cancer treated only by TUR, the rate of intravesical recurrence did not differ significantly between patients with high ACTN4 expression and patients with low ACTN4 expression. In patients who had muscle‑invasive tumors and underwent radical cystectomy, high ACTN4 expression was associated with neither recurrence nor poor prognosis. Nonetheless, high ACTN4 expression was shown by a large percentage (81%) of patients with muscle-invasive bladder cancer and by a small percentage (17%) of patients with superficial bladder cancer. Furthermore, the leading edges of the invasive bladder cancer showed increased ACTN4 expression. ACTN4 suppression significantly reduced the number of invading bladder cancer cells but unexpectedly increased the proliferation of bladder cancer cells. ACTN4 suppression increased the phosphorylation of ERKs but not AKT or STAT3, suggesting that the increased proliferation due to ACTN4 suppression was mediated in part by the ERK pathway. ACTN4 expression may suppress the proliferation of bladder cancer cells and may produce conditions which facilitate cancer cell invasion.

View Figures

View References

1	Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA and Ashamallah A: Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol. 158:393–399. 1997. View Article : Google Scholar : PubMed/NCBI
2	Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 19:666–675. 2001.PubMed/NCBI
3	Takahashi A, Tsukamoto T, Tobisu K, et al: Radical cystectomy for invasive bladder cancer: results of multi-institutional pooled analysis. Jpn J Clin Oncol. 34:14–19. 2004. View Article : Google Scholar : PubMed/NCBI
4	Rosenberg JE, Carroll PR and Small EJ: Update on chemotherapy for advanced bladder cancer. J Urol. 174:14–20. 2005. View Article : Google Scholar : PubMed/NCBI
5	von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 18:3068–3077. 2000.
6	von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 23:4602–4608. 2005.
7	Ito K, Fujita T, Akada M, et al: Identification of bladder cancer antigens recognized by IgG antibodies of a patient with metastatic bladder cancer. Int J Cancer. 108:712–724. 2004. View Article : Google Scholar : PubMed/NCBI
8	Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
9	Scanlan MJ, Chen YT, Williamson B, et al: Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer. 76:652–658. 1998. View Article : Google Scholar : PubMed/NCBI
10	Honda K, Yamada T, Endo R, et al: Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol. 140:1383–1393. 1998. View Article : Google Scholar : PubMed/NCBI
11	Araki N, Hatae T, Yamada T and Hirohashi S: Actinin-4 is preferentially involved in circular ruffling and macropinocytosis in mouse macrophages: analysis by fluorescence ratio imaging. J Cell Sci. 113:3329–3340. 2000.PubMed/NCBI
12	Wang SE, Shin I, Wu FY, Friedman DB and Arteaga CL: HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor β. Cancer Res. 66:9591–9600. 2006.PubMed/NCBI
13	Yamagata N, Shyr Y, Yanagisawa K, et al: A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res. 9:4695–4704. 2003.PubMed/NCBI
14	Honda K, Yamada T, Hayashida Y, et al: Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology. 128:51–62. 2005. View Article : Google Scholar : PubMed/NCBI
15	Koizumi T, Nakatsuji H, Fukawa T, et al: The role of actinin-4 in bladder cancer invasion. Urology. 75:357–364. 2010. View Article : Google Scholar : PubMed/NCBI
16	Bubeník J, Baresová M, Viklický V, et al: Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer. 11:765–773. 1973.PubMed/NCBI
17	Tachibana M, Miyakawa A, Nakashima J, et al: Constitutive production of multiple cytokines and a human chorionic gonadotrophin beta-subunit by a human bladder cancer cell line (KU-19-19): possible demonstration of totipotential differentiation. Br J Cancer. 76:163–174. 1997. View Article : Google Scholar
18	Kikuchi S, Honda K, Tsuda H, et al: Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res. 14:5348–5356. 2008. View Article : Google Scholar : PubMed/NCBI
19	Horiguchi A, Sumitomo M, Asakuma J, et al: Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway. J Urol. 176:1636–1641. 2006. View Article : Google Scholar : PubMed/NCBI
20	Yamamoto S, Tsuda H, Honda K, et al: Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol. 22:499–507. 2009. View Article : Google Scholar : PubMed/NCBI
21	Hayashida Y, Honda K, Idogawa M, et al: E-cadherin regulates the association between β-catenin and actinin-4. Cancer Res. 65:8836–8845. 2005.
22	Hatakeyama H, Kondo T, Fujii K, et al: Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics. 6:6300–6316. 2006. View Article : Google Scholar
23	Nikolopoulos SN, Spengler BA, Kisselbach K, Evans AE, Biedler JL and Ross RA: The human non-muscle α-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells. Oncogene. 19:380–386. 2000.
24	Hara T, Honda K, Shitashige M, et al: Mass spectrometry analysis of the native protein complex containing actinin-4 in prostate cancer cells. Mol Cell Proteomics. 6:479–491. 2007. View Article : Google Scholar : PubMed/NCBI
25	Jasavala R, Martinez H, Thumar J, et al: Identification of putative androgen receptor interaction protein modules: cytoskeleton and endosomes modulate androgen receptor signaling in prostate cancer cells. Mol Cell Proteomics. 6:252–271. 2007. View Article : Google Scholar
26	Teramoto H, Malek RL, Behbahani B, Castellone MD, Lee NH and Gutkind JS: Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes. Oncogene. 22:2689–2697. 2003. View Article : Google Scholar : PubMed/NCBI